[PDF][PDF] Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Journal of clinical oncology, 1998•Citeseer
Conclusion: First-course docetaxel PK is a predictor of first-course hematologic toxicity, but
also of fluid retention, which is cumulative in nature. Patients with elevated hepatic enzymes
have a 27% reduction in docetaxel CL and are at a higher risk of toxicity. A starting dose of
75 mg/m 2 is currently being evaluated in this population. Prospective implementation of
largescale population PK/PD evaluation is feasible in early drug development and this
approach generates clinically relevant findings.
also of fluid retention, which is cumulative in nature. Patients with elevated hepatic enzymes
have a 27% reduction in docetaxel CL and are at a higher risk of toxicity. A starting dose of
75 mg/m 2 is currently being evaluated in this population. Prospective implementation of
largescale population PK/PD evaluation is feasible in early drug development and this
approach generates clinically relevant findings.
Conclusion: First-course docetaxel PK is a predictor of first-course hematologic toxicity, but also of fluid retention, which is cumulative in nature. Patients with elevated hepatic enzymes have a 27% reduction in docetaxel CL and are at a higher risk of toxicity. A starting dose of 75 mg/m 2 is currently being evaluated in this population. Prospective implementation of largescale population PK/PD evaluation is feasible in early drug development and this approach generates clinically relevant findings.
Citeseer